Patents by Inventor Emma Nordahl

Emma Nordahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE PROTEASE
    Publication number: 20230302100
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: November 8, 2022
    Publication date: September 28, 2023
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Cysteine protease
    Patent number: 11667905
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: June 6, 2023
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Cysteine protease
    Patent number: 11524057
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: December 13, 2022
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • CYSTEINE PROTEASE
    Publication number: 20220170004
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: December 14, 2021
    Publication date: June 2, 2022
    Inventors: Christian Kjellman, Sofia Jamum, Emma Nordahl
  • Cysteine protease
    Patent number: 11214784
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: January 4, 2022
    Assignee: Hansa BioPharma AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • CYSTEINE PROTEASE
    Publication number: 20200283749
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 10, 2020
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Cysteine proteases
    Patent number: 10758597
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 1, 2020
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • Cysteine protease
    Patent number: 10696959
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: June 30, 2020
    Assignee: HANSA BIOPHARMA AB
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • CYSTEINE PROTEASE
    Publication number: 20200179497
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: February 17, 2020
    Publication date: June 11, 2020
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • CYSTEINE PROTEASE
    Publication number: 20180037962
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 8, 2018
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl
  • CYSTEINE PROTEASE
    Publication number: 20180023070
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 25, 2018
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Nordahl